325 related articles for article (PubMed ID: 7989750)
1. H-2 allele-specific protection from NK cell lysis in vitro for lymphoblasts but not tumor targets. Protection mediated by alpha 1/alpha 2 domains.
Sentman CL; Olsson MY; Salcedo M; Höglund P; Lendahl U; Käre K
J Immunol; 1994 Dec; 153(12):5482-90. PubMed ID: 7989750
[TBL] [Abstract][Full Text] [Related]
2. H-2Dp transgene alters natural killer cell specificity at the target and effector cell levels. Comparison with an H-2Dd transgene.
Sentman CL; Olsson-Alheim MY; Lendahl U; Kärre K
J Immunol; 1996 Apr; 156(7):2423-9. PubMed ID: 8786300
[TBL] [Abstract][Full Text] [Related]
3. The MHC class I molecule H-2Dp inhibits murine NK cells via the inhibitory receptor Ly49A.
Olsson-Alheim MY; Sundbäck J; Kärre K; Sentman CL
J Immunol; 1999 Jun; 162(12):7010-4. PubMed ID: 10358142
[TBL] [Abstract][Full Text] [Related]
4. NK cell receptor calibration: effects of MHC class I induction on killing by Ly49Ahigh and Ly49Alow NK cells.
Olsson-Alheim MY; Salcedo M; Ljunggren HG; Kärre K; Sentman CL
J Immunol; 1997 Oct; 159(7):3189-94. PubMed ID: 9317116
[TBL] [Abstract][Full Text] [Related]
5. NK cells from human MHC class I (HLA-B) transgenic mice do not mediate hybrid resistance killing against parental nontransgenic cells.
Kung SK; Su RC; Graham JJ; Chamberlain JW; Miller RG
J Immunol; 1998 Jan; 160(2):674-80. PubMed ID: 9551902
[TBL] [Abstract][Full Text] [Related]
6. Role of major histocompatibility complex class I alpha 1/alpha 2 domain polymorphism and in vivo expression pattern in tumor resistance: studies with transgenic mice and lymphoma cell transfectants.
Höglund P; Waldenström M; Kärre K
J Immunother Emphasis Tumor Immunol; 1993 Oct; 14(3):175-81. PubMed ID: 8297899
[TBL] [Abstract][Full Text] [Related]
7. MHC class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells.
Karlhofer FM; Ribaudo RK; Yokoyama WM
Nature; 1992 Jul; 358(6381):66-70. PubMed ID: 1614533
[TBL] [Abstract][Full Text] [Related]
8. Influence of glycosylphosphatidylinositol-linked H-2Dd molecules on target cell protection and natural killer cell specificity in transgenic mice.
Sentman CL; Olsson-Alheim MY; Lendahl U; Kärre K
Eur J Immunol; 1996 Sep; 26(9):2127-32. PubMed ID: 8814257
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneity of lymphokine-activated killer cells induced by IL-2. Separate lymphoid subpopulations lyse tumor, allogeneic blasts, and modified syngeneic blasts.
LeFor AT; Eisenthal A; Rosenberg SA
J Immunol; 1988 Jun; 140(11):4062-9. PubMed ID: 3259603
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of natural killer cell-mediated bone marrow graft rejection by allogeneic major histocompatibility complex class I, but not class II molecules.
Ohlén C; Höglund P; Sentman CL; Carbone E; Ljunggren HG; Koller B; Kärre K
Eur J Immunol; 1995 May; 25(5):1286-91. PubMed ID: 7774631
[TBL] [Abstract][Full Text] [Related]
11. Positive recognition of MHC class I molecules by the Ly49D receptor of murine NK cells.
George TC; Mason LH; Ortaldo JR; Kumar V; Bennett M
J Immunol; 1999 Feb; 162(4):2035-43. PubMed ID: 9973475
[TBL] [Abstract][Full Text] [Related]
12. Host MHC class I molecules modulate in vivo expression of a NK cell receptor.
Karlhofer FM; Hunziker R; Reichlin A; Margulies DH; Yokoyama WM
J Immunol; 1994 Sep; 153(6):2407-16. PubMed ID: 8077656
[TBL] [Abstract][Full Text] [Related]
13. The ability of H-2Dd molecule to affect natural resistance to hemopoietic allografts is an intrinsic property shared by Ddm1 but not Ld.
Milisauskas VK; Nakamura I
Eur J Immunol; 1994 Feb; 24(2):336-42. PubMed ID: 8299682
[TBL] [Abstract][Full Text] [Related]
14. Tolerance and alloreactivity of the Ly49D subset of murine NK cells.
George TC; Ortaldo JR; Lemieux S; Kumar V; Bennett M
J Immunol; 1999 Aug; 163(4):1859-67. PubMed ID: 10438920
[TBL] [Abstract][Full Text] [Related]
15. Afferent and efferent cellular interactions in natural resistance directed against MHC class I deficient tumor grafts.
Ljunggren HG; Ohlén C; Höglund P; Yamasaki T; Klein G; Kärre K
J Immunol; 1988 Jan; 140(2):671-8. PubMed ID: 3335786
[TBL] [Abstract][Full Text] [Related]
16. Rejection of tumors in mice with severe combined immunodeficiency syndrome determined by the major histocompatibility complex. Class I expression on the graft.
Glas R; Waldenström M; Höglund P; Klein G; Kärre K; Ljunggren HG
Cancer Res; 1995 May; 55(9):1911-6. PubMed ID: 7728758
[TBL] [Abstract][Full Text] [Related]
17. NK 1+ CD4- CD8- alphabeta T cells in the peritoneal cavity: specific T cell receptor-mediated cytotoxicity and selective IFN-gamma production against B cell leukemia and myeloma cells.
Sugie T; Kubota H; Sato M; Nakamura E; Imamura M; Minato N
J Immunol; 1996 Nov; 157(9):3925-35. PubMed ID: 8892624
[TBL] [Abstract][Full Text] [Related]
18. External and internal calibration of the MHC class I-specific receptor Ly49A on murine natural killer cells.
Kåse A; Johansson MH; Olsson-Alheim MY; Kärre K; Höglund P
J Immunol; 1998 Dec; 161(11):6133-8. PubMed ID: 9834098
[TBL] [Abstract][Full Text] [Related]
19. Loss or mismatch of MHC class I is sufficient to trigger NK cell-mediated rejection of resting lymphocytes in vivo - role of KARAP/DAP12-dependent and -independent pathways.
Oberg L; Johansson S; Michaëlsson J; Tomasello E; Vivier E; Kärre K; Höglund P
Eur J Immunol; 2004 Jun; 34(6):1646-53. PubMed ID: 15162434
[TBL] [Abstract][Full Text] [Related]
20. Multiple natural killer cell-activating signals are inhibited by major histocompatibility complex class I expression in target cells.
Correa I; Corral L; Raulet DH
Eur J Immunol; 1994 Jun; 24(6):1323-31. PubMed ID: 8206092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
